Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2013, XXXIV/201: 135-139 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2013, XXXIV/201: 135-139

Title: Current state of research on multiple sclerosis

Authors: Lubina-Dąbrowska N., Stępień A., Chalimoniuk M.

More details

01/201

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Current state of research on multiple sclerosis


Lubina-Dąbrowska N.1, Stępień A.1, Chalimoniuk M.2

1Military Institute of Medicine in Warsaw, Poland, Central Clinical Hospital of the Ministry of National Defense, Department of Neurolog; 2University of Cardinal Stefan Wyszynski, Warsaw, Poland, Department of Biology and Environmental Sciences

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) autoimmune. It belongs to a group of demyelinating disease, which is an irreversible consequence of disability. Epidemiological data indicate that occurs in nearly 2.5 million people around the world. Despite much research is still little known about the disease pathomechanism. Do not we also have so far fully effective the treatment. Available immunomodulatory drugs offer new opportunities defer progression for years. Both fingolimod and natalizumab are more effective in the treatment of MS than the widely used IFN-β and glatiramer acetate (GA). However, new drugs pose a greater risk of side effects than first-generation drugs. The rapid development of research offers the prospect of a better understanding of the pathogenesis of the disease and to develop more effective treatments.

Key words: Multiple sclerosis (MS), diagnosis, immunomodulating therapy, cytokines, IFN-β

Pol. Merk. Lek., 2013, XXXIV, 201, 135